MARKET

NKTR

NKTR

Nektar Therapeutics
NASDAQ
43.42
+1.14
+2.70%
After Hours: 43.42 0 0.00% 19:01 01/02 EST
OPEN
42.49
PREV CLOSE
42.28
HIGH
44.27
LOW
41.51
VOLUME
715.62K
TURNOVER
--
52 WEEK HIGH
66.92
52 WEEK LOW
6.48
MARKET CAP
883.23M
P/E (TTM)
-5.4778
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NKTR last week (1222-1226)?
Weekly Report · 12/29/2025 09:38
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar
NASDAQ · 12/26/2025 07:33
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow
NASDAQ · 12/24/2025 15:51
Nektar Therapeutics (NKTR) Stock Slides Despite Analyst Optimism On Alopecia Data
Benzinga · 12/22/2025 21:19
Weekly Report: what happened at NKTR last week (1215-1219)?
Weekly Report · 12/22/2025 09:38
Nektar Therapeutics: Rezpeg's Phase 2b Alopecia Areata Results Leave Many Questions
Seeking Alpha · 12/19/2025 15:35
Nektar Therapeutics: Alopecia Update And A Look At The Road Ahead For Rezpeg
Seeking Alpha · 12/17/2025 21:49
Jefferies Sticks to Its Buy Rating for Nektar Therapeutics (NKTR)
TipRanks · 12/17/2025 13:45
More
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

Webull offers Nektar Therapeutics stock information, including NASDAQ: NKTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NKTR stock methods without spending real money on the virtual paper trading platform.